SciSparc shifts strategy to pursue the agentic AI market and establishes an AI‑cybersecurity advisory board
Executive summary: SciSparc Ltd.’s board of directors decided to target the agentic AI market and formed a scientific advisory board for artificial intelligence and cybersecurity. The move signals a strategic pivot toward a fast‑growing AI segment, potentially opening new revenue streams and requiring expertise to manage AI‑related security challenges.
Who is involved: SciSparc Ltd. (Nasdaq: SPRC), its board of directors, and the newly constituted scientific advisory board (composed of AI and cybersecurity experts).
Likely next: The advisory board will convene to shape SciSparc’s AI product roadmap, with possible follow‑on announcements of partnerships, technology developments, or pilot projects in the agentic AI space.
The company’s board has authorized a move into agentic artificial intelligence, a nascent sub‑field focused on autonomous AI agents, and concurrently created a scientific advisory board to guide its AI and cybersecurity initiatives. This dual focus reflects an attempt to capture growth in high‑value AI applications while addressing associated security risks. The announcement comes as SciSparc continues its existing neuro‑therapy clinical programs, indicating a broader diversification effort.
Timeline
- — SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity (GlobeNewswire)
Analysis — what this means
Sectors affected
- Agentic AI
- AI cybersecurity
- AI data training
Historical parallels
- SciSparc’s NeuroThera Labs initiated a Phase IIb clinical trial for Tourette syndrome treatment at Hannover Medical School on July 15, 2026.